Back to TECH
TECH Stock Analysis: Growth, Valuation and Risks
$TECHNEUTRALBiotechnology

TECH Stock Analysis: Growth, Valuation and Risks

Bio-Techne’s shares closed near their 52-week high as analysts weighed recent operating results and progress on a Merck KGaA merger deal. Growth and liquidity are positive, but earnings trends, premium valuation, and price targets below the close leave the outlook mixed.

November 14, 202611 min read
Current Price
$72.80
+0.05%
Analyst Rating
Hold
Price Target
$70.29
-3.4% upside
P/E Ratio
66.18

Executive Summary

Investment Thesis: Bio-Techne supplies research tools, reagents, and diagnostics used across life-science research and clinical testing. Recent coverage described Q1 fiscal 2027 revenue and earnings as beating estimates, while available financial data show revenue growth of 4.6% but earnings growth of negative 25%. The shares closed near their 52-week high, yet a P/E of 66.18 and an analyst mean target below the close point to limited near-term valuation support. The balance of these factors is mixed, and the merger process and next earnings report are important items to monitor.

Current Price: $72.80, as of Friday, November 13 | Key Metric: Forward P/E 31.48 | Stance: NEUTRAL

This report is dated Saturday, November 14, 2026. US stock markets were closed that day, so the quoted $72.80 is the supplied latest price for Friday, November 13, not a Saturday trading price. The provided daily change was +$0.04, or +0.05%, from the previous close of $72.76.

Company Overview

Bio-Techne Corporation develops and sells specialized products and services for life-science research, biopharmaceutical development, and diagnostic testing. Its offerings include proteins, antibodies, reagents, instruments, and related assays used by research laboratories and healthcare customers. Demand is tied to research activity, bioprocessing, and adoption of diagnostic technologies.

Key Products & Competitive Position

  • Core Business: Life-science tools and diagnostic products, including materials used to study biological processes and support research workflows.
  • Key Products: The company is associated with brands and product lines including R&D Systems, ProteinSimple, and Advanced Cell Diagnostics. These cover proteins and reagents, analytical instruments, and molecular diagnostic technologies.
  • Competitive Moat: Established product catalogs, technical expertise, customer familiarity, and integration into laboratory workflows can support repeat purchasing. The strength of that advantage depends on product performance, customer budgets, and the ability to keep pace with competing technologies.

Recent Developments

News coverage dated November 9 described Bio-Techne’s first quarter of fiscal 2027 as a revenue and earnings beat, citing growth in Protein Sciences, and said a merger deal with Merck KGaA was advancing. The supplied information does not include transaction terms, a definitive timetable, or regulatory milestones, so the financial and ownership implications cannot be assessed here. Investors following the company may want to distinguish announced progress from a completed transaction.

Financial Snapshot

Market Cap$11.44B
P/E Ratio66.18
52-Week Range$43.20 - $72.88
Dividend Yield0.55%
EPS (TTM)$1.10
ROE8.22%

Revenue & Earnings Trends

Yahoo Finance data in the supplied research show revenue of approximately $1.23 billion and revenue growth of 4.6%. Gross margin was 66.17%, while EBITDA margin was 26.49%, suggesting the company retains substantial gross profit on sales and converts a portion into operating cash earnings. However, reported earnings growth was negative 25.0%, and quarterly earnings growth was negative 25.9%. That gap between positive sales growth and weaker earnings makes margin performance and cost control important to track.

Trailing EPS is reported at $1.09 by the additional data source and $1.10 in the supplied key metrics. These are close but not identical, likely reflecting rounding or data timing. For consistency, this report uses $1.10 as the requested snapshot figure. Fiscal Q1 2027 coverage characterized results as a beat, while the earnings record supplied separately labels EPS of $0.44 against a $0.44 estimate as a miss. The figures are equal as displayed, so the classification appears to reflect the source’s underlying precision or methodology rather than a visible numerical shortfall.

Balance Sheet Highlights

Bio-Techne’s current ratio of 2.28 and quick ratio of 1.53 indicate that reported current assets exceed short-term obligations, although these ratios alone do not establish the quality or availability of those assets. The additional data list $351.1 million in cash, $285.6 million in debt, and a debt-to-equity ratio of 13.19%. Free cash flow was approximately $277.8 million and operating cash flow about $337.6 million. These figures suggest cash generation and moderate reported debt, but should be read alongside the company’s capital needs and any transaction-related financing disclosures.

Valuation Analysis

Current Valuation Metrics

Forward P/E31.48Industry comparison not supplied
PEG Ratio2.18Growth-adjusted, source reported
EV/EBITDA34.95Historical comparison not supplied
P/S Ratio9.26Peer comparison not supplied

Historical Comparison

A five-year valuation average was not provided, so a precise comparison with Bio-Techne’s own historical multiples would be speculative. The supplied two-year average closing price was $61.09, below the November 13 close, but a price comparison is not a substitute for comparing earnings, cash flow, or sales multiples across time. The current trailing P/E of 66.18 and enterprise value to EBITDA of 34.95 indicate that the market is assigning a substantial valuation to the business relative to current earnings measures.

Fair Value Estimate

The supplied analyst mean target is $70.29, about 3.4% below the $72.80 close. The target range provided is $62 to $73, though another data source lists a low target of $50 and a mean of $70.50. This difference highlights the sensitivity of consensus summaries to provider coverage and timing. As a rough reference rather than a definitive fair value, the available target data place the shares around the low $60s to low $70s. A DCF estimate cannot be responsibly calculated from the information supplied because forward cash flows, discount rate assumptions, and long-term growth estimates are missing.

Competitive Landscape

Market Position

Market Share: Not available in the supplied data | Ranking: Exact industry ranking not established by the supplied data

Key Competitors

Danaher (DHR)Danaher provides life-science, diagnostics, and laboratory products across a broad portfolio.
Thermo Fisher Scientific (TMO)Thermo Fisher Scientific serves research, laboratory, diagnostics, and biopharma customers at global scale.
Revvity (RVTY)Revvity offers life-science research and diagnostic technologies that overlap in selected markets.

Competitive Advantages

  • Specialized Catalog: A broad set of research products can make Bio-Techne a convenient supplier for laboratories with varied needs.
  • Workflow Familiarity: Products incorporated into established laboratory methods may benefit from repeat use and switching costs, though alternatives remain available.
  • Technical Know-How: Experience in proteins, reagents, instruments, and diagnostic applications can support product development and customer service. The advantage must be maintained through reliable quality and innovation.

Earnings Track Record

Last 4 Quarters: 0 independently verified beats / 1 source-labeled miss or tie; three quarters of comparable estimates and actuals were not provided.

Recent Earnings History

Q1 FY2027, reported Nov. 6$0.44 vs $0.44 estimate in supplied dataSOURCE-LABELED MISS; NEWS REPORT DESCRIBES BEAT
Prior quarterActual and estimate not suppliedNOT AVAILABLE
Two quarters priorActual and estimate not suppliedNOT AVAILABLE
Three quarters priorActual and estimate not suppliedNOT AVAILABLE

Guidance Trend

No management guidance revisions or long-term numerical outlook were included in the supplied material. The next listed report is expected on February 3, 2027, with an EPS estimate of $0.49. That estimate is not company guidance, and comparisons with the reported $0.44 require attention to quarter length, consensus timing, and any updated analyst assumptions.

Analyst Sentiment

Consensus Rating: Hold

Strong Buy: 0 Buy: 0 Hold: 12 Sell: 1

The supplied analyst tally covers 13 opinions and is concentrated in Hold ratings. The additional Yahoo Finance extract reports 10 opinions and a mean target of $70.50, rather than the supplied $70.29. Both target means are below the latest close, but the disagreement in coverage counts and target lows means consensus should be treated as a snapshot, not a precise forecast.

Price Targets

  • Low: $62, according to the supplied analyst target summary; another source lists $50
  • Mean: $70.29 (-3.4% implied change from $72.80)
  • High: $73

Recent Analyst Actions

No individual analyst upgrades, downgrades, or changes to price targets were provided. The available consensus is therefore more informative about the overall distribution than about any recent change in analyst opinion.

Recent News & Catalysts

Key Developments

  • Q1 fiscal 2027 results: November 9 coverage reported that earnings and revenue beat estimates, with Protein Sciences growth cited as a contributor. The supplied EPS detail shows $0.44 against a $0.44 estimate and labels the result a miss, so the precise earnings surprise is unclear in the available figures.
  • Merger process: The same Bio-Techne news item said its merger deal with Merck KGaA was advancing. No terms, closing date, or approvals were included, leaving execution and transaction impacts as open questions.
  • Unrelated company notice: A November 12 CMB.TECH Q3 results announcement also appeared in the supplied news feed. It concerns a different company and is not a Bio-Techne catalyst.

Upcoming Catalysts

Next Earnings: February 3, 2027, expected | Key Events: FY2027 Q2 results and any further disclosed milestones on the Merck KGaA merger process

For the week beginning Monday, November 16, no specific Bio-Techne event was listed. Because the US market was closed on Saturday, November 14, any new company disclosures over the weekend would be separate from Friday’s trading. The date of the next earnings report and deal-related announcements may change, so company filings remain the authoritative source.

Technical Outlook

Current Price: $72.80 as of Friday, November 13 vs 52-Week High: $72.88 (0.1% below the high)

Trend Analysis

The supplied 52-week range places the close near its upper boundary and about 68.5% above the $43.20 low. The additional data report a 24.21% 52-week change, indicating meaningful appreciation over that period. Near-high positioning can reflect positive momentum, but it can also leave the price more exposed to disappointment if earnings, deal progress, or sector conditions fail to support the current valuation. Beta of 1.27 indicates historically higher volatility than the broad market, though beta is not a guarantee of future moves.

Key Levels

  • Resistance: Around $72.88 to $73, the supplied 52-week high and analyst high target; a longer-term reference near $77.88 appears in the additional Yahoo extract as a two-year highest close.
  • Support: Around $70 as a nearby round-number reference, then the low $60s as a broader zone that overlaps the supplied analyst low target. These are approximate reference levels, not verified chart-derived support points.

Bull vs Bear Case

Bull Case

  • Operating resilience: Revenue growth of 4.6% and gross margin of 66.17% show continued sales and product-level profitability, despite lower reported earnings growth.
  • Research demand and portfolio: Continued demand for research tools, Protein Sciences products, and diagnostic technologies could support growth if customer budgets and adoption remain healthy.
  • Strategic transaction: Progress on the Merck KGaA merger deal could change the company’s strategic and financial outlook, although terms and closing conditions are not available here.

Bull Scenario Reference: $84, an illustrative 15.4% above $72.80, not an analyst consensus target or forecast

Bear Case

  • Weak earnings trend: Earnings growth is reported at negative 25.0%, while quarterly earnings growth is negative 25.9%, raising questions about the pace of profit recovery.
  • Execution and deal uncertainty: Merger timing, approvals, and eventual financial effects are not specified. Delays or unfavorable terms could weigh on expectations.
  • Valuation sensitivity: A trailing P/E of 66.18 and EV/EBITDA of 34.95 leave less room for operational disappointment than lower-multiple valuations would.

Bear Scenario Reference: $58, an illustrative 20.3% below $72.80, not an analyst consensus target or forecast

The scenario references are sensitivity examples, not price predictions. What would change the balance most? Evidence that earnings growth is stabilizing, or confirmation that it is deteriorating further, would help clarify whether the premium valuation is supported by fundamentals.

Risks to Consider

  • Valuation Risk: The current share price is near the 52-week high while trailing valuation multiples are elevated. If projected earnings do not materialize, the multiple could contract even without a severe decline in revenue.
  • Competitive Risk: Large, diversified companies such as Danaher and Thermo Fisher compete across relevant laboratory and life-science markets. Product substitution, pricing pressure, or faster innovation by competitors could affect growth and margins.
  • Macro Risk: Research budgets, biotechnology funding, and pharmaceutical spending can shift with economic conditions and financing availability. Bio-Techne’s beta of 1.27 also signals meaningful historical sensitivity to market changes.
  • Execution Risk: The company must maintain product quality, develop relevant technologies, and manage costs while pursuing its strategy. The merger process adds uncertainty because terms and timing are not supplied.

Bottom Line

Investment Verdict: NEUTRAL

Bio-Techne combines a specialized life-science portfolio, positive but modest sales growth, and reported cash generation with weaker earnings growth and a premium valuation. Shares closed close to their 52-week high, while the supplied analyst mean target is slightly lower, and the available merger details are limited. This assessment is informational analysis, not investment advice or a recommendation to buy, sell, or hold any security.

Action Items for Investors

  • Long-term investors: Track revenue and earnings conversion, margin trends, and cash flow over multiple quarters. Review company filings for the merger’s terms and conditions rather than relying on brief news summaries.
  • Short-term traders: Treat the $72.88 to $73 area as a reference near the reported 52-week high, not as a guaranteed resistance level. The next scheduled earnings date is in February, and price volatility can change before then.
  • Risk management: Compare position exposure with your own risk limits and account for the stock’s 1.27 beta and valuation sensitivity. This is a general analytical consideration, not personalized financial advice.

What to Watch This Week

  • Any new Bio-Techne or regulatory disclosure clarifying the Merck KGaA merger’s terms, timetable, or required approvals.
  • Company filings or updated data that reconcile the Q1 fiscal 2027 earnings classification and provide more detail on revenue and margin performance.
  • Price behavior relative to the $72.88 52-week high and the broader market when US trading resumes Monday, November 16; markets were closed Saturday and Sunday.

Data note: Financial, earnings, and analyst figures in this report come from the information supplied for November 14, 2026, including a Yahoo Finance extract. Some sources report different analyst counts, target lows, and target means. Metrics may also vary by calculation method and reporting date. Verify current figures in company filings and other primary sources. This report is for informational purposes only and is not investment advice.

Share this report

Share this article

Spread the word on social media

Think TECH will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.